The investigation of the predictable markers of Sitagliptin effect on glycemic control

The investigation of the predictable markers of Sitagliptin effect on glycemic control - The investigation of the predictable markers of Sitagliptin effect on glycemic control

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006004

Enrollment

Registered

2011-07-20

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

Duration 24 weeks Type 2 Diabetes Mellitus Drug therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whom drug therapy is indicated

Exclusion criteria

Exclusion criteria: Patient who has the impairment of renal function (male Cr > 2.5mg/dl, female Cr 2.0mg/dl or Ccr < 30ml/min) Patient who has nephrotic syndrome Patient who has hypoalbuminemia Patient who has cirrhosis Patient who has malignancy Patient who has pregnant , nurses a baby or may get pregnant Patient who is unsuitable for this study (judged by a doctor)

Design outcomes

Primary

Measure	Time frame
To elucidate the predictable markers of Sitagliptin effect on glycemic control	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026